Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1293 vs Lantus in Type 1 Diabetes
NCT02059161Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2013
- Primary completion
- May 2015
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of lusduna nexvue in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 and Percentage of Participants With Any Confirmed Positive Anti-insulin Antibody (AIA) at 24 weeks. Started Oct 2013; status: completed.
02
Drugs
lusduna nexvue
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02059161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059161.